9.4900
07-May-25 16:00:08
15 minutes delayed
Stocks
+0.3800
+4.17%
Today's range
8.7700 - 9.7000
ISIN
N/A
Source
NASDAQ
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
31 Mar 2025 07:30:00 By Nasdaq GlobeNewswire
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
07 Feb 2025 08:00:00 By Nasdaq GlobeNewswire